Recurrent Meningioma
SMO/AKT/ NF2/CDK INHIBITORS FOR PROGRESSIVE MENINGIOMAS
A Phase II open label trial that studies how well vismodegib, focal adhesion kinase (FAK) inhibitor GSK2256098, and Capivasertib work in treating patients with progressive Meningioma.
Learn More
RIBOCICLIB FOR RECURRENT MENINGIOMA
A Phase 0/2 study of ribociclib in preoperative Rb-positive recurrent high-grade meningioma patients scheduled for resection.